H.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (RCUS) to Buy from Neutral with a price target of $24, up from $18. The ARC-20 ...

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Daniel Benedict Arcus pleaded not guilty to three counts of sexual intercourse without consent when his jury trial began in ...

Arcus Biosciences Inc (NYSE:RCUS) is set to release its Q4 2024 earnings on Feb 25, 2025. The consensus estimate for Q4 2024 ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...